Fig. 1
From: Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
BET Bromodomain Inhibition Downregulates PD-L1 Expression in Prostate Cancer. a Relative PD-L1 MFI (normalized to DMSO control) in DU145 cells treated with indicated agents, gated on live cells. N = 1 sample / iteration, repeated × 3. b Representative histograms of PD-L1 expression in DU145 cells incubated with JQ1 and/or IFNγ gated on live cells. c Summary flow cytometry data for B, N = 1 sample / iteration, repeated × 8. d PD-L1 expression in PC3 cells incubated with JQ1 and/or IFNγ, gated on live cells. e Summary flow cytometry data for D, N = 1 sample / iteration, repeated × 8. f PD-L1 (CD274) mRNA levels in DU145. Fold-change normalized to 18 s and to control (DMSO) treatment. N = 3 / group, repeated × 2. g PD-L1 (CD274) mRNA levels in PC3. Normalized to control (DMSO). N = 3 / group, repeated × 2. * p < 0.05, **p < 0.01, *** p < 0.001, ****p < 0.0001. Error bars = standard deviation